Singaporean startup ImmunoScape raises $14M to advance capabilities
Singaporean startup ImmunoScape raises $14M to advance capabilities 19 April 2021 | News Round is co-led by EDBI, Anzu Partners and UTEC, representing major biotech innovation centers across the U.S., Singapore and Japan
Image credit- shutterstock.com
ImmunoScape, a Singapore headquartered biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, has announced it has completed a $14 million fundraising round led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an investment arm of the Economic Development Board of Singapore. The new round brings ImmunoScape’s total funding in the past year to $25 million.
Fresh $18m fund injection for Singapore biotech firm doing Covid-19 research
straitstimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from straitstimes.com Daily Mail and Mail on Sunday newspapers.
ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.